MeSH tree: C04.557.595.500
A dendritic cell vaccine administered before and after autologous stem cell transplant (ASCT) was safe and immunogenic and was associated with durable clinical responses in patients with high-risk multiple myeloma, according ...
Sep 22, 2023
0
51
Cancer patients appeared to benefit from natural killer cells obtained from donors in an experimental method of treating cancer that involved an aggressive army of immune system fighters endowed with the ability to home in ...
Survival outcomes using chimeric antigen receptor-T cell therapy (CAR-T cell therapy) continue to be impressive for patients with some blood cancers.
Sep 15, 2023
0
2
When Michel Sadelain began his decades-long quest to genetically modify immune cells to fight cancer, his peers dismissed his ideas as absurd and even his mother grew concerned for his career.
Sep 14, 2023
0
24
A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other top-tier cancer centers highlights the vital role that the immune system plays in determining ...
Sep 6, 2023
0
48
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are part of an international team of scientists who identified mechanisms by which some multiple myelomas become resistant ...
Aug 31, 2023
0
31
A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed ...
Aug 30, 2023
0
60
Melbourne researchers have designed a single drug that delivers a lethal "one-two" punch to several types of blood cancer in preclinical studies and could lead to improved treatments.
Aug 30, 2023
0
23
The U.S. Food and Drug Administration has approved Talvey (talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma.
Aug 16, 2023
0
2
Younger adults with newly diagnosed multiple myeloma who receive an autologous stem cell transplant (auto-HCT) have a median progression-free survival (PFS) of approximately 3.5 years and a median overall survival (OS) of ...
Jul 27, 2023
0
23
